1v0o
From Proteopedia
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
| - | Plasmodium falciparum cell cycle regulators are promising targets for, antimalarial drug design. We have determined the structure of PfPK5, the, first structure of a P. falciparum protein kinase and the first of a, cyclin-dependent kinase (CDK) not derived from humans. The fold and the, mechanism of inactivation of monomeric CDKs are highly conserved across, evolution. ATP-competitive CDK inhibitors have been developed as potential, leads for cancer therapeutics. These studies have identified regions of, the CDK active site that can be exploited to achieve significant gains in, inhibitor potency and selectivity. We have cocrystallized PfPK5 with three, inhibitors that target such regions. The sequence differences between, PfPK5 and human CDKs within these inhibitor binding sites suggest ... | + | Plasmodium falciparum cell cycle regulators are promising targets for, antimalarial drug design. We have determined the structure of PfPK5, the, first structure of a P. falciparum protein kinase and the first of a, cyclin-dependent kinase (CDK) not derived from humans. The fold and the, mechanism of inactivation of monomeric CDKs are highly conserved across, evolution. ATP-competitive CDK inhibitors have been developed as potential, leads for cancer therapeutics. These studies have identified regions of, the CDK active site that can be exploited to achieve significant gains in, inhibitor potency and selectivity. We have cocrystallized PfPK5 with three, inhibitors that target such regions. The sequence differences between, PfPK5 and human CDKs within these inhibitor binding sites suggest that, selective inhibition is an attainable goal. Such compounds will be useful, tools for P. falciparum cell cycle studies, and will provide lead, compounds for antimalarial drug development. |
==About this Structure== | ==About this Structure== | ||
| - | 1V0O is a | + | 1V0O is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum] with INR as [http://en.wikipedia.org/wiki/ligand ligand]. Structure known Active Site: INA. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1V0O OCA]. |
==Reference== | ==Reference== | ||
| Line 27: | Line 27: | ||
[[Category: transferase]] | [[Category: transferase]] | ||
| - | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 5 14:45:53 2007'' |
Revision as of 12:40, 5 November 2007
|
STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
Overview
Plasmodium falciparum cell cycle regulators are promising targets for, antimalarial drug design. We have determined the structure of PfPK5, the, first structure of a P. falciparum protein kinase and the first of a, cyclin-dependent kinase (CDK) not derived from humans. The fold and the, mechanism of inactivation of monomeric CDKs are highly conserved across, evolution. ATP-competitive CDK inhibitors have been developed as potential, leads for cancer therapeutics. These studies have identified regions of, the CDK active site that can be exploited to achieve significant gains in, inhibitor potency and selectivity. We have cocrystallized PfPK5 with three, inhibitors that target such regions. The sequence differences between, PfPK5 and human CDKs within these inhibitor binding sites suggest that, selective inhibition is an attainable goal. Such compounds will be useful, tools for P. falciparum cell cycle studies, and will provide lead, compounds for antimalarial drug development.
About this Structure
1V0O is a Single protein structure of sequence from Plasmodium falciparum with INR as ligand. Structure known Active Site: INA. Full crystallographic information is available from OCA.
Reference
Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition., Holton S, Merckx A, Burgess D, Doerig C, Noble M, Endicott J, Structure. 2003 Nov;11(11):1329-37. PMID:14604523
Page seeded by OCA on Mon Nov 5 14:45:53 2007
